NI
NTLA icon

Numeric Investors’s Intellia Therapeutics NTLA Stock Holding History

Numeric Investors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$6.5M Buy
338,448
+318,014
+1,556% +$7.34M 0.05% 369
2017
Q3 		$508K Buy
+20,434
New +$385K ﹤0.01% 874

Other funds holding NTLA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Numeric Investors's NTLA Position: Q4 2017 in Review

Numeric Investors increased its Intellia Therapeutics (NTLA) stake by 1,556% in Q4 2017, buying an estimated $7.34M and bringing the position to 338,448 shares worth $6.5M. The position accounts for 0.05% of the portfolio, ranked #369.

Numeric Investors first reported a position in NTLA in Q3 2017 and has held it in 2 quarters since. 112 funds tracked by Wall St. Rank hold NTLA as of Q4 2017.

  • Numeric Investors held 338,448 shares of Intellia Therapeutics worth $6.5M as of Q4 2017.
  • Numeric Investors bought 318,014 Intellia Therapeutics shares in Q4 2017, an estimated $7.34M.
  • Intellia Therapeutics made up 0.05% of Numeric Investors's portfolio in Q4 2017, its #369 holding.
  • Numeric Investors first reported a position in Intellia Therapeutics in Q3 2017 and has held it in 2 quarters since.
  • 112 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2017.

Based on Numeric Investors's 13F filing for Q4 2017, filed 14 Feb 2018.